UPDATE: Stifel Downgrades Biogen (BIIB) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/15/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- Lucid Group shares quickly cut in half on report of potential bankruptcy
- Kosovo bans Serb minister over ethnic cleansing remarks
Trial Design Likely Boosted Biogen (BIIB) BIIB037 Efficacy Data - Nomura
March 20, 2015 8:01 AM EDTWhile many are signing the praises of Biogen (NASDAQ: BIIB) this morning following Phase Ib data for BIIB037 in Alzheimers disease (AD), Nomura analyst M. Ian Somaiya is not so sanguine - asking "was it the drug or the trial design?"
Somaiya commented, " The Phase Ib efficacy data exceeded even the most bullish... More
Biogen (BIIB) PT Raised to $500 at Barclays on 'Impressive' AD Data
March 20, 2015 7:34 AM EDTBarclays analyst Geoffrey Meacham reiterated an Overweight rating and boosted his price target on Biogen (NASDAQ: BIIB) to $500.00 (from $435.00) following "impressive' AD data.
"The data provided quantitative evidence of a statistically significant benefit vs placebo at 54 weeks on key connotative endpoints...",... More
Biogen (BIIB) BIIB-037 Data Shows Strong Efficacy, Very Good Safety, Says RBC
March 20, 2015 7:01 AM EDTRBC Capital maintained an Outperform rating on Biogen (NASDAQ: BIIB) with a price target of $445. Comments follow the release of BIIB-037 data in Alzheimers disease. Analyst Michael J. Yee noted data showed strong efficacy and very good safety.
"We are at the AD/PD conf in Europe & there are a few... More
Biogen Idec (BIIB) Reports Statistically Significant Data from Aducanumab Phase 1b
March 20, 2015 5:53 AM EDTBiogen Idec (NASDAQ: BIIB) announced data from a pre-specified interim analysis of PRIME, the Phase 1b study of aducanumab (BIIB037), in which aducanumab demonstrated an acceptable safety profile and positive results on radiologic and clinical measurements in patients with prodromal or mild Alzheimers disease (AD). These data are being presented today at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Nice, France.
Treatment with aducanumab produced a dose- and time-dependent reduction of amyloid plaque in the brain. Amyloid plaque is... More
